Monitor Genmab's upcoming earnings release for royalty revenue recognition and any guidance updates. The DARZALEX sales trajectory is a key indicator of Genmab's financial health, but this filing alone provides no comparative data or forward-looking statements.
Price Chart
Executive Summary
Genmab disclosed Q2 2026 worldwide net sales of DARZALEX at USD 4,207 million, with USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. The company receives royalties on these sales from Johnson & Johnson. This is a routine quarterly sales update without comparative data or guidance, providing a top-line indicator of Genmab's primary revenue driver.
Key Facts
- Worldwide net trade sales of DARZALEX in Q2 2026 totaled USD 4,207 million.
- U.S. net sales were USD 2,435 million; rest of world net sales were USD 1,772 million.
- Genmab receives royalties on worldwide DARZALEX sales under its license with Johnson & Johnson (Janssen).
Financial Impact
DARZALEX Q2 2026 net sales of USD 4,207 million; Genmab's royalty revenue depends on these sales, but the filing does not disclose Genmab's own financials.
Risk Factors
- Heavy reliance on DARZALEX royalties for revenue.
- Potential competition from biosimilars or alternative therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000102 |
| Document: gmab_20260715x6k.htm | 0001434265-26-000102 |
| Document: 0001434265-26-000102-index-headers.html | 0001434265-26-000102 |
| Document: 0001434265-26-000102-index.html | 0001434265-26-000102 |
| Document: 0001434265-26-000102.txt | 0001434265-26-000102 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $33.53 $32.65 | ▼ −2.62% | ▼ −1.96% | $34.51 (+2.94%) |
Aug 12, 2026 7w ago | 6-K | $31.42 $34.11 | ▲ +8.56% | ▲ +9.01% | $34.51 (+9.85%) |
Aug 11, 2026 7w ago | 6-K | $30.85 $32.96 | ▲ +6.84% | ▲ +7.24% | $34.51 (+11.88%) |
Aug 6, 2026 8w ago | 6-K | $29.83 $31.34 | ▲ +5.06% | ▲ +3.85% | $34.51 (+15.71%) |
Jul 15, 2026 11w ago | 6-K | $29.08 $28.85 | ▼ −0.79% | ▲ +0.19% | $34.51 (+18.69%) |
Jun 29, 2026 13w ago | 6-K | $27.47 $28.01 | ▲ +1.97% | ▲ +1.36% | $34.51 (+25.65%) |
Jun 17, 2026 15w ago | 6-K | $25.39 $25.87 | ▲ +1.87% | ▲ +2.91% | $34.51 (+35.94%) |
Jun 16, 2026 15w ago | 6-K | $24.74 $25.94 | ▲ +4.85% | ▲ +7.08% | $34.51 (+39.51%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.51 (+40.42%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.51 (+40.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access